Quali-quantitative synthesis of the global panorama of clinical trials on leprosy
Autor(a) principal: | |
---|---|
Data de Publicação: | 2023 |
Outros Autores: | , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Brazilian Journal of Health Review |
Texto Completo: | https://ojs.brazilianjournals.com.br/ojs/index.php/BJHR/article/view/59183 |
Resumo: | The work presents the analysis and synthesis of clinical trials about leprosy worldwide in the last 20 years. Three technological aspects for study were defined, namely: diagnosis, drug/treatment and vaccine. Seventy-one (71) clinical trials were identified (11 for diagnosis, 54 for drug and 6 for vaccine), distributed among 62 main sponsors, 70 secondary sponsors and 21 countries, with 14 countries participating in 7 international consortia. For the recovery of clinical trials, the ICTRP® platform of the World Health Organization was used. Through quantitative and qualitative analysis and synthesis, a pattern of similarity was observed between 6 types of indicators highlighted in the figurative elements of the article. Eighteen types of final results (3 genera and 18 species) and 9 phases of clinical development were mapped. The most significant participation of non-hegemonic nations was found, which corroborates and validates the state of the art on the investment dedicated to the diseases of neglected populations. A temporal prospecting of two decades was adopted, although records were only identified in 15 years. In this time cut, 9 inflection points were identified, which demonstrates an oscillating development agenda, which presupposes an inconstant interest of the hegemonic pharmaceutical industry in favor of the struggle against leprosy that devastate neglected populations. It is concluded that the clinical effort aimed at leprosy is "corrective", because "treatment" has the most significant amount of clinical trials, and in the background is the "preventive" clinical effort, which represent the subquantities related to the categories "vaccine” and “diagnosis”. Therefore, it appears that the quali-quantitative analysis and synthesis allows us to assert that the clinical development scenario dedicated to leprosy deserves special attention from the State and other real factors of power, in order to create more effective public policies in favor of the neglected populations affected by leprosy. In summary, it is suggested that new public policies shall be created to encourage synergy between clinical trials, both national and international, in order to induce a safe path to clinical-therapeutic independence and, consequently, better performance in the struggle against leprosy in Brazil. |
id |
BJRH-0_96c11e3f2ebe4af180a27090feb75ef2 |
---|---|
oai_identifier_str |
oai:ojs2.ojs.brazilianjournals.com.br:article/59183 |
network_acronym_str |
BJRH-0 |
network_name_str |
Brazilian Journal of Health Review |
repository_id_str |
|
spelling |
Quali-quantitative synthesis of the global panorama of clinical trials on leprosyleprosyclinical trialThe work presents the analysis and synthesis of clinical trials about leprosy worldwide in the last 20 years. Three technological aspects for study were defined, namely: diagnosis, drug/treatment and vaccine. Seventy-one (71) clinical trials were identified (11 for diagnosis, 54 for drug and 6 for vaccine), distributed among 62 main sponsors, 70 secondary sponsors and 21 countries, with 14 countries participating in 7 international consortia. For the recovery of clinical trials, the ICTRP® platform of the World Health Organization was used. Through quantitative and qualitative analysis and synthesis, a pattern of similarity was observed between 6 types of indicators highlighted in the figurative elements of the article. Eighteen types of final results (3 genera and 18 species) and 9 phases of clinical development were mapped. The most significant participation of non-hegemonic nations was found, which corroborates and validates the state of the art on the investment dedicated to the diseases of neglected populations. A temporal prospecting of two decades was adopted, although records were only identified in 15 years. In this time cut, 9 inflection points were identified, which demonstrates an oscillating development agenda, which presupposes an inconstant interest of the hegemonic pharmaceutical industry in favor of the struggle against leprosy that devastate neglected populations. It is concluded that the clinical effort aimed at leprosy is "corrective", because "treatment" has the most significant amount of clinical trials, and in the background is the "preventive" clinical effort, which represent the subquantities related to the categories "vaccine” and “diagnosis”. Therefore, it appears that the quali-quantitative analysis and synthesis allows us to assert that the clinical development scenario dedicated to leprosy deserves special attention from the State and other real factors of power, in order to create more effective public policies in favor of the neglected populations affected by leprosy. In summary, it is suggested that new public policies shall be created to encourage synergy between clinical trials, both national and international, in order to induce a safe path to clinical-therapeutic independence and, consequently, better performance in the struggle against leprosy in Brazil.Brazilian Journals Publicações de Periódicos e Editora Ltda.2023-04-26info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://ojs.brazilianjournals.com.br/ojs/index.php/BJHR/article/view/5918310.34119/bjhrv6n2-300Brazilian Journal of Health Review; Vol. 6 No. 2 (2023); 8200-8223Brazilian Journal of Health Review; Vol. 6 Núm. 2 (2023); 8200-8223Brazilian Journal of Health Review; v. 6 n. 2 (2023); 8200-82232595-6825reponame:Brazilian Journal of Health Reviewinstname:Federação das Indústrias do Estado do Paraná (FIEP)instacron:BJRHenghttps://ojs.brazilianjournals.com.br/ojs/index.php/BJHR/article/view/59183/42916Meneghin, Rogério AlmeidaFrade, Marco Andrey CiprianiCohen, Mirian Mirandade Oliveira e Dias, Ana Elisa XavierLonga, Leila Costa Duarteinfo:eu-repo/semantics/openAccess2023-04-26T17:39:56Zoai:ojs2.ojs.brazilianjournals.com.br:article/59183Revistahttp://www.brazilianjournals.com/index.php/BJHR/indexPRIhttps://ojs.brazilianjournals.com.br/ojs/index.php/BJHR/oai|| brazilianjhr@gmail.com2595-68252595-6825opendoar:2023-04-26T17:39:56Brazilian Journal of Health Review - Federação das Indústrias do Estado do Paraná (FIEP)false |
dc.title.none.fl_str_mv |
Quali-quantitative synthesis of the global panorama of clinical trials on leprosy |
title |
Quali-quantitative synthesis of the global panorama of clinical trials on leprosy |
spellingShingle |
Quali-quantitative synthesis of the global panorama of clinical trials on leprosy Meneghin, Rogério Almeida leprosy clinical trial |
title_short |
Quali-quantitative synthesis of the global panorama of clinical trials on leprosy |
title_full |
Quali-quantitative synthesis of the global panorama of clinical trials on leprosy |
title_fullStr |
Quali-quantitative synthesis of the global panorama of clinical trials on leprosy |
title_full_unstemmed |
Quali-quantitative synthesis of the global panorama of clinical trials on leprosy |
title_sort |
Quali-quantitative synthesis of the global panorama of clinical trials on leprosy |
author |
Meneghin, Rogério Almeida |
author_facet |
Meneghin, Rogério Almeida Frade, Marco Andrey Cipriani Cohen, Mirian Miranda de Oliveira e Dias, Ana Elisa Xavier Longa, Leila Costa Duarte |
author_role |
author |
author2 |
Frade, Marco Andrey Cipriani Cohen, Mirian Miranda de Oliveira e Dias, Ana Elisa Xavier Longa, Leila Costa Duarte |
author2_role |
author author author author |
dc.contributor.author.fl_str_mv |
Meneghin, Rogério Almeida Frade, Marco Andrey Cipriani Cohen, Mirian Miranda de Oliveira e Dias, Ana Elisa Xavier Longa, Leila Costa Duarte |
dc.subject.por.fl_str_mv |
leprosy clinical trial |
topic |
leprosy clinical trial |
description |
The work presents the analysis and synthesis of clinical trials about leprosy worldwide in the last 20 years. Three technological aspects for study were defined, namely: diagnosis, drug/treatment and vaccine. Seventy-one (71) clinical trials were identified (11 for diagnosis, 54 for drug and 6 for vaccine), distributed among 62 main sponsors, 70 secondary sponsors and 21 countries, with 14 countries participating in 7 international consortia. For the recovery of clinical trials, the ICTRP® platform of the World Health Organization was used. Through quantitative and qualitative analysis and synthesis, a pattern of similarity was observed between 6 types of indicators highlighted in the figurative elements of the article. Eighteen types of final results (3 genera and 18 species) and 9 phases of clinical development were mapped. The most significant participation of non-hegemonic nations was found, which corroborates and validates the state of the art on the investment dedicated to the diseases of neglected populations. A temporal prospecting of two decades was adopted, although records were only identified in 15 years. In this time cut, 9 inflection points were identified, which demonstrates an oscillating development agenda, which presupposes an inconstant interest of the hegemonic pharmaceutical industry in favor of the struggle against leprosy that devastate neglected populations. It is concluded that the clinical effort aimed at leprosy is "corrective", because "treatment" has the most significant amount of clinical trials, and in the background is the "preventive" clinical effort, which represent the subquantities related to the categories "vaccine” and “diagnosis”. Therefore, it appears that the quali-quantitative analysis and synthesis allows us to assert that the clinical development scenario dedicated to leprosy deserves special attention from the State and other real factors of power, in order to create more effective public policies in favor of the neglected populations affected by leprosy. In summary, it is suggested that new public policies shall be created to encourage synergy between clinical trials, both national and international, in order to induce a safe path to clinical-therapeutic independence and, consequently, better performance in the struggle against leprosy in Brazil. |
publishDate |
2023 |
dc.date.none.fl_str_mv |
2023-04-26 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://ojs.brazilianjournals.com.br/ojs/index.php/BJHR/article/view/59183 10.34119/bjhrv6n2-300 |
url |
https://ojs.brazilianjournals.com.br/ojs/index.php/BJHR/article/view/59183 |
identifier_str_mv |
10.34119/bjhrv6n2-300 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
https://ojs.brazilianjournals.com.br/ojs/index.php/BJHR/article/view/59183/42916 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Brazilian Journals Publicações de Periódicos e Editora Ltda. |
publisher.none.fl_str_mv |
Brazilian Journals Publicações de Periódicos e Editora Ltda. |
dc.source.none.fl_str_mv |
Brazilian Journal of Health Review; Vol. 6 No. 2 (2023); 8200-8223 Brazilian Journal of Health Review; Vol. 6 Núm. 2 (2023); 8200-8223 Brazilian Journal of Health Review; v. 6 n. 2 (2023); 8200-8223 2595-6825 reponame:Brazilian Journal of Health Review instname:Federação das Indústrias do Estado do Paraná (FIEP) instacron:BJRH |
instname_str |
Federação das Indústrias do Estado do Paraná (FIEP) |
instacron_str |
BJRH |
institution |
BJRH |
reponame_str |
Brazilian Journal of Health Review |
collection |
Brazilian Journal of Health Review |
repository.name.fl_str_mv |
Brazilian Journal of Health Review - Federação das Indústrias do Estado do Paraná (FIEP) |
repository.mail.fl_str_mv |
|| brazilianjhr@gmail.com |
_version_ |
1797240028937584640 |